Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Triple Negative Breast Neoplasms 1Solid Tumor 1Prostatic Neoplasms, Castration-Resistant 1Pancreatic Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Nivolumab 7toripalimab 5Injections 5tislelizumab 3pembrolizumab 3spartalizumab 2Paclitaxel 2Ipilimumab 2Gemcitabine 2Cisplatin 2zimberelimab 1ulocuplumab 1sotorasib 1sintilimab 1osimertinib 1famitinib 1donafenib 1cemiplimab 1binimetinib 1avelumab 1atezolizumab 1WW Domain-Containing Oxidoreductase 1Taxes 1SHR-1701 1Oxaliplatin 1N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide 1LY-2157299 1Immunotherapy, Adoptive 1Cetuximab 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Solid Tumor × zimberelimab × Clear all
NCT05909436 2023-06-18

Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors

Guangzhou Gloria Biosciences Co., Ltd.

Phase 1/2 Recruiting
107 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡